Small interference RNA targeting Krüppel-like factor 8 inhibits the renal carcinoma 786-0 cells growth in vitro and in vivo. 2010

Wei-Jin Fu, and Jia-Chu Li, and Xiao-Yun Wu, and Zhan-Bing Yang, and Zeng-Nan Mo, and Jiong-Wei Huang, and Guo-Wei Xia, and Qiang Ding, and Kang-Da Liu, and Hong-Guang Zhu
Department of Urology, The First Affiliated Hospital of Guangxi Medical University, Guangxi, People's Republic of China.

OBJECTIVE Krüppel-like factor 8 (KLF8) plays an important role in oncogenic transformation and is highly overexpressed in several types of human cancer. We investigated the expression of KLF8 in renal cell carcinoma (RCC) tissues and the role of small interference RNA targeting KLF8 on growth, cell cycle, and apoptosis of human renal carcinoma cell line 786-0 in vitro and in vivo. METHODS The expression of KLF8 protein and mRNA in human renal carcinoma samples was detected by immunochemistry and reverse transcription polymerase chain reaction (RT-PCR). The effects of small interference RNA (siRNA) targeting KLF8 on growth, invasiveness, cell cycle, and apoptosis of 786-0 cells were evaluated by MTT assay, Matrigel Invasion Assay, and flow cytometry in vitro. We also investigated effect of siRNA targeting KLF8 on growth of 786-0 cells in nude mice in vivo. RESULTS Immunohistochemistry and RT-PCR results showed the expression of KLF8 protein and mRNA in RCC specimens was significantly higher than that in the adjacent non-tumorous renal tissues (P < 0.001). KLF8-siRNA depressed the cellular growth and invasion of 786-0 cells in vitro. The flow cytometry results revealed that KLF8-siRNA could induce an increase in G0/G1 phase cells and induce cell apoptosis. Intratumor injection of siRNA targeting KLF8 inhibited the growth of 786-0 cells in vivo in nude mice tumor model. CONCLUSIONS KLF8 possibly involved in regulating the cell growth, invasion, apoptosis, and proliferation of renal carcinoma cancer cells. Blocking the KLF8 channel might be a potential therapeutic strategy for RCC.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D007680 Kidney Neoplasms Tumors or cancers of the KIDNEY. Cancer of Kidney,Kidney Cancer,Renal Cancer,Cancer of the Kidney,Neoplasms, Kidney,Renal Neoplasms,Cancer, Kidney,Cancer, Renal,Cancers, Kidney,Cancers, Renal,Kidney Cancers,Kidney Neoplasm,Neoplasm, Kidney,Neoplasm, Renal,Neoplasms, Renal,Renal Cancers,Renal Neoplasm
D008297 Male Males
D008819 Mice, Nude Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses. Athymic Mice,Mice, Athymic,Nude Mice,Mouse, Athymic,Mouse, Nude,Athymic Mouse,Nude Mouse
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D012097 Repressor Proteins Proteins which maintain the transcriptional quiescence of specific GENES or OPERONS. Classical repressor proteins are DNA-binding proteins that are normally bound to the OPERATOR REGION of an operon, or the ENHANCER SEQUENCES of a gene until a signal occurs that causes their release. Repressor Molecules,Transcriptional Silencing Factors,Proteins, Repressor,Silencing Factors, Transcriptional
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

Wei-Jin Fu, and Jia-Chu Li, and Xiao-Yun Wu, and Zhan-Bing Yang, and Zeng-Nan Mo, and Jiong-Wei Huang, and Guo-Wei Xia, and Qiang Ding, and Kang-Da Liu, and Hong-Guang Zhu
February 2012, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine,
Wei-Jin Fu, and Jia-Chu Li, and Xiao-Yun Wu, and Zhan-Bing Yang, and Zeng-Nan Mo, and Jiong-Wei Huang, and Guo-Wei Xia, and Qiang Ding, and Kang-Da Liu, and Hong-Guang Zhu
February 2012, Molecular medicine reports,
Wei-Jin Fu, and Jia-Chu Li, and Xiao-Yun Wu, and Zhan-Bing Yang, and Zeng-Nan Mo, and Jiong-Wei Huang, and Guo-Wei Xia, and Qiang Ding, and Kang-Da Liu, and Hong-Guang Zhu
May 2011, Journal of experimental & clinical cancer research : CR,
Wei-Jin Fu, and Jia-Chu Li, and Xiao-Yun Wu, and Zhan-Bing Yang, and Zeng-Nan Mo, and Jiong-Wei Huang, and Guo-Wei Xia, and Qiang Ding, and Kang-Da Liu, and Hong-Guang Zhu
June 2015, Oncology letters,
Wei-Jin Fu, and Jia-Chu Li, and Xiao-Yun Wu, and Zhan-Bing Yang, and Zeng-Nan Mo, and Jiong-Wei Huang, and Guo-Wei Xia, and Qiang Ding, and Kang-Da Liu, and Hong-Guang Zhu
August 2018, Oncology research,
Wei-Jin Fu, and Jia-Chu Li, and Xiao-Yun Wu, and Zhan-Bing Yang, and Zeng-Nan Mo, and Jiong-Wei Huang, and Guo-Wei Xia, and Qiang Ding, and Kang-Da Liu, and Hong-Guang Zhu
January 2009, Pathology, research and practice,
Wei-Jin Fu, and Jia-Chu Li, and Xiao-Yun Wu, and Zhan-Bing Yang, and Zeng-Nan Mo, and Jiong-Wei Huang, and Guo-Wei Xia, and Qiang Ding, and Kang-Da Liu, and Hong-Guang Zhu
September 2019, Oncology letters,
Wei-Jin Fu, and Jia-Chu Li, and Xiao-Yun Wu, and Zhan-Bing Yang, and Zeng-Nan Mo, and Jiong-Wei Huang, and Guo-Wei Xia, and Qiang Ding, and Kang-Da Liu, and Hong-Guang Zhu
April 2007, Anti-cancer drugs,
Wei-Jin Fu, and Jia-Chu Li, and Xiao-Yun Wu, and Zhan-Bing Yang, and Zeng-Nan Mo, and Jiong-Wei Huang, and Guo-Wei Xia, and Qiang Ding, and Kang-Da Liu, and Hong-Guang Zhu
August 2005, Cancer gene therapy,
Wei-Jin Fu, and Jia-Chu Li, and Xiao-Yun Wu, and Zhan-Bing Yang, and Zeng-Nan Mo, and Jiong-Wei Huang, and Guo-Wei Xia, and Qiang Ding, and Kang-Da Liu, and Hong-Guang Zhu
February 2008, Molecular cancer,
Copied contents to your clipboard!